Intercept Pharmaceuticals
450 W 15th Street
Suite 505
New York City
New York
10011
United States
Tel: 646-747-1000
Fax: 646-747-1001
Website: https://www.interceptpharma.com/
Email: info@interceptpharma.com
171 articles with Intercept Pharmaceuticals
-
In an 8-K filing with the U.S. Securities and Exchange Commission, Intercept Pharmaceuticals said it will eliminate approximately 170 employees as part of an effort to streamline the company’s operations and reduce operating expenses.
-
Wrapping up June and ahead of the July 4 holiday, the U.S. Food and Drug Administration (FDA) has a busy two-week period coming up for drug approvals. Here’s a look.
-
The U.S. Food and Drug Administration has a busy week of possible drug approvals on its calendar. Here’s a look.
-
Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
12/10/2019
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced that it will host a NASH Commercial Day for investors on Monday, December 16, 2019 from 9:00 a.m. to 12:30 p.m. ET in New York City..
-
Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019
10/28/2019
New analyses from Phase 3 REGENERATE study evaluating the effects of OCA on non-invasive liver fibrosis tests and NASH patient-reported outcomes
-
As the International Liver Conference continues to unfold in Vienna, multiple companies are presenting data on potential treatments that can address numerous needs. BioSpace takes a look at some of the data.
-
Intercept Pharma plans to seek regulatory approval in the U.S. and Europe in the second half of this year.
-
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
-
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
-
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
-
Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
-
Intercept Pharmaceuticals Reports Full Year and Fourth Quarter 2017 Financial Results and Provides Business Update
2/14/2018
Intercept recorded $129.2 million of worldwide net Ocaliva sales for the full year 2017, and $37.3 million for the fourth quarter of 2017.
-
Intercept Announces Phase III REVERSE Trial Evaluating OCA for the Treatment of NASH Patients With Compensated Cirrhosis
2/12/2018
REVERSE is a randomized, double-blind, placebo-controlled, multi-center study that will evaluate the efficacy and safety of the investigational therapy OCA in approximately 540 patients with a biopsy-confirmed diagnosis of cirrhosis due to NASH.
-
Intercept to Report 2017 Full Year Financial Results on February 14 and Present at Upcoming Conferences
2/8/2018
Management will conduct a conference call and audio webcast on Wednesday, February 14, 2018 at 8:30 a.m. Eastern Time to discuss these results.
-
Intercept Announces Updated U.S. Prescribing Information for Ocaliva (obeticholic acid) to Reinforce Appropriate Dosing in PBC Patients With Advanced Cirrhosis
2/2/2018
In the postmarketing setting, hepatic decompensation and failure have been reported in patients with advanced cirrhosis when Ocaliva was dosed more frequently than the recommended starting dosage.
-
The decision was largely expected given the time of the year and the fact the trial hasn't yet been initiated.
-
Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some added holiday cheer.
-
Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
11/27/2017
Dr. Weyer most recently served as President and Chief Development Officer of ProSciento,
-
At 14.1%, healthcare is the third largest weighted sector in the S&P 500 index, and with 76 million baby boomers getting older and living longer, owning healthcare stocks in your portfolio makes sense.
-
Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
11/1/2017
Intercept recorded $40.9 million of worldwide net Ocaliva sales, including a change in estimate related to deferred revenue with a net effect of a one-time increase of $4.1 million in net revenue for the quarter.